Lastly, the third trial involves DFV890 (an NLRP3 inhibitor) and MAS825 (an anti-IL-1β/IL-18 agent), targeting patients with CH and coronary heart disease (NCT06097663). The gene discussed is IL1B; the disease is cyclic hematopoiesis.